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INTRODUCTION
Neuraxial analgesia has been demonstrated for
many years to be the only safe and effective way to
provide labour analgesia (1). However, labour
epidural analgesia relying on high doses of local
anaesthetics (LA) produced motor block interfering
with labour and the mode of delivery.
To reduce these side effects, adjuvants are rou-
tinely combined with local anaesthetics since more
than 20 years.
New LA has become available during the last
10 years and new modes of administration of anal-
gesics have also gained in popularity during the last
decade i.e. patient-controlled epidural analgesia
(PCEA) and combined spinal-epidural (CSE).
Therefore, an adequate understanding of those
improvements is required to provide the optimal
neuraxial analgesia during labour and delivery.
DRUGS
Local anaesthetics
The last ten years have been marked by the
arrival of two new local anaesthetics (LA), ropiva-
caine (Naropin®) and levobupivacaine (Chiro-
caine®). Their advantages would be a reduced sys-
temic toxicity and a better preservation of motor
function. For those reasons, they have been chal-
lenging bupivacaine (Marcaine®) as the most wide-
ly used LA in obstetric analgesia so far (2, 3). The
majority of authors agree that toxicity is not an
issue when low doses and concentrations of local
anaesthetics are used as it is the case for modern
neuraxial obstetrical analgesia. The benefits of
reduced motor impairment with ropivacaine remain
controversial. A first meta-analysis reported obstet-
rical and neonatal benefits with ropivacaine com-
pared with bupivacaine when used at “historical”
high concentrations (0.25%) (4). These results were
not confirmed by a subsequent meta-analysis or
randomised trials that failed to identify any differ-
ence between both drugs in terms of obstetrical out-
come when “modern” dilute concentrations are
used (5-7).
Ropivacaine and levobupivacaine have been
reported to be less potent than bupivacaine when
compared using the MLAC model (8-9). However,
this difference in potencies has not been confirmed
is when these drugs are used at clinically useful
concentrations.
A study reported less motor block with ropiva-
caine 0.08% plus fentanyl 2 µg/ml than with same
concentration of bupivacaine plus fentanyl when
this block is evaluated on a 6 points modified
Bromage’s scale or by the ability to ambulate (10).
However, another study that took into account
a reduced potency of ropivacaine and compared
“equipotent” dilute solutions i.e. bupivacaine
0.0625% vs ropivacaine 0.1% failed to demonstrate
any difference on the ability to ambulate (11).
These minor and controversial differences in
clinical outcome and the differences of cost of these
new agents have led several authors to divergent
conclusions regarding the place of the most recent-
ly marketed LA for labour analgesia (12-14).
Therefore, it seems evident that the adequate
dilution of local anaesthetics and the strategies aim-
ing to reduce their consumption are more important
than the choice of the local anaesthetic by itself
when the goal is to provide optimal neuraxial
obstetrical analgesia.
Several strategies have been proposed to
reduce the LA concentration and consumption i.e.
the admixture of adjuvants such as lipophilic opi-
oids, clonidine, adrenaline and neostigmine to
epidural local anaesthetics.
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Opioids
Fentanyl and sufentanil used in combination
with LA allow effective analgesia using concentra-
tion of LA that would otherwise be sub-therapeutic.
Their use has become routine from the mid 80’s.
This approach reduces motor blockade and the
incidence of instrumental delivery compared with
LA-only solutions (15). Pruritus is the most com-
mon side effect of opioids and is dose dependent.
Potential maternal and neonatal respiratory depres-
sion must also be considered. Epidural sufentanil
doses ranging from 7.5 µg to 30 µg have been
reported to improved quality of analgesia as well as
reduce motor block and instrumental deliveries (16-
17). Sufentanil 0.75 µg/ml has been described by
some authors as the optimal concentration when
combined with bupivacaine 0.125% administered in
intermittent top up (18). However, others reported
that reducing sufentanil concentration to
0.156 µg/ml reduced pruritus without altering the
quality of patient-controlled epidural analgesia with
bupivacaine 0.125% (19).
Dose-dependent reduction of the MLAC of
bupivacaine has been reported for sufentanil con-
centrations between 0.5 µg/ml and 1.5 µg/ml and
for fentanyl concentrations between 1 µg/ml and
4 µg/ml when administered in a 20 ml volume (20-
21).
Epinephrine
Epinephrine is another widely accepted adju-
vant for neuraxial analgesia. It decreases dural
blood flow which is responsible for clearance of
epidural drugs and makes more drug to be able to
diffuse to the CNS. Moreover, it has a direct anal-
gesic and produces segmental analgesia. One possi-
ble mechanism is an effect on the a2-adrenergic
receptors in the dorsal horn. Epinephrine enhances
central antinociception, reduces vascular uptake of
analgesics, increases the neuronal block induced
with LA and decreases their risk of systemic toxic-
ity. It has also been widely used to detect intra-
venous injection of LA. Side effects related to epi-
nephrine administration are a reduced uterine blood
flow and a reduce uterine contractility. Epinephrine
is also responsible of an increased incidence of
motor block, maternal hypotension, pruritus,nausea
and vomiting. These controversial side effects seem
to be dose-related and apparent in concentrations up
to 1/300.000.
Therefore the addition of epinephrine to LA
and/or opioids remains questionable and even more
with the new LA that possess intrinsic vasoconstric-
tor properties (22).
Clonidine
Epidural administration of clonidine, an a2-
agonist, has also been largely investigated (23).
Its analgesic properties have been well demon-
strated by its sparing effect on the MLAC as well as
on the LA consumption.
However clonidine has a very narrow thera-
peutic range, as it is ineffective with bolus below
60 µg and is responsible for increased incidence of
maternal hypotension and sedation as well as fetal
heart rate alterations with bolus higher than 75 µg
or repeated administrations (24-29). Moreover
clonidine has not been approved by the FDA for use
in obstetric analgesia. Recently, analgesic efficacy
and side effects of sufentanil and clonidine has been
compared.
75 µg clonidine or 5 µg sufentanil produces
similar reduction of the MLAC of ropivacaine (30).
Administered at these equianalgesic doses, cloni-
dine induces more frequent and severe maternal
hypotension while sufentanil is responsible for
more frequent pruritus (31). For those reasons,
clonidine is not a first choice adjuvant for epidural
administration (32).
Concerning intrathecal administration of
clonidine, doses as low as 15 to 30 µg have been
reported to increase incidence of maternal hypoten-
sion, ephedrine requirements and incidence of fetal
heart rate abnormalities (33-34). Therefore admin-
istration of intrathecal clonidine during labour is
not recommended.
Neostigmine
The opioid, noradrenergic and adenosine anal-
gesic systems involve cholinergic stimulation of
nicotinic and muscarinic receptors in spinal cord
interneurons. Neostigmine, a cholinesterase inhibi-
tor, has demonstrated interesting neuraxial anal-
gesic properties. 
Epidural administration of neostigmine at
doses ranging from 500 to 750 µg combined with
10 µg sufentanil provides reasonable early labour
analgesia without any significant maternal or fetal
side effect. Nevertheless, the side effects associated
with repeated doses or continuous infusion remain
to be determined (35-37).
Intrathecal administration of neostigmine
alone at the dose of 10 µg is ineffective and pro-
vides inconstant enhancement of analgesia with
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sufentanil and bupivacaine. Moreover this intrathe-
cal administration is associated with an unaccept-
able high incidence of nausea unresponsive to
antiemetics. These side effects preclude its intrathe-
cal use (37).
MODE OF ADMINISTRATION
If the choice of drugs, concentrations and
combinations is of the highest importance, their
mode of administration is also very important.
Patient-controlled epidural analgesia sometimes
following a spinal administration of an opioid with
or without LA (combined spinal-epidural : CSE)
has replaced the historical intermittent “top-ups” or
continuous infusions in order to improve analgesia
while reducing LA consumption and motor impair-
ment.
Combined spinal epidural
Combined spinal epidural (CSE) for labour
analgesia is slowly gaining popularity. Analgesia is
initiated with a spinal administration of an opioid
sometimes combined with a LA. Thereafter, analge-
sia is maintained via an epidural catheter. This tech-
nique allows a faster initiation of analgesia with
spinal opioid alone in early labour and a reduction
of anaesthetic requirements as compared to epidural
analgesia.
The preservation of mobility and consequent-
ly the ability to ambulate was supposed to offer
benefits on labour evolution and mode of delivery.
Unfortunately, no randomised trial has been able to
confirm that theory (38-41).
It must be kept in mind that CSE has been
reported to be responsible of a higher incidence of
fetal heart rate abnormalities and uterine hyperac-
tivity especially with sufentanil doses higher than
5 µg. The spinal administration of LA may be asso-
ciated with an increased incidence of motor
block (42-44). Here again, the adequate combina-
tion of LA and opioids makes possible to provide
adequate analgesia while reducing the side effects
of each drug. 
PCEA
Patient controlled epidural analgesia has
become the gold standard to provide labour epi-
dural analgesia. This mode of administration is
superior to intermittent top-ups in terms of maternal
satisfaction (45) and to continuous infusion in
terms of local anaesthetics consumption and inci-
dence of motor block (46). Controversy still
remains about the usefulness of a background infu-
sion. Initial studies addressing this issue favoured
PCEA without basal rate with bupivacaine 0.125%
plus sufentanil and with ropivacaine 0.1% plus
sufentanil while more recent publications evaluat-
ing lower concentrations of LA favoured PCEA
with basal rate (47-53).
CONCLUSIONS
All those considerations on the pharmacody-
namic properties of the different analgesics that can
be used for neuraxial analgesia demonstrate clearly
that it does not exist one single “magic bullet” able
to provide ideal analgesia and that an optimal com-
bination of drugs is needed to obtain the adequate
analgesia without interfering with labour evolution
or the mode of delivery and without inducing
maternal or neonatal side effects.
Optimal method of administration is at least as
important as it plays a major role on the quality of
analgesia, maternal satisfaction and incidence of
side-effects.
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